MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) today announced the publication of three MorphoSys abstracts which were submitted to the 56th American Society of Hematology (ASH) Annual Meeting and Exposition to take place on December 6-9 in San Francisco, California. These abstracts include first clinical data on the Company’s proprietary drug candidate MOR208 from a Phase 2a study in patients with Non-Hodgkin’s Lymphoma (NHL) and final data from the Phase 1/2a clinical trial in Chronic Lymphocytic Leukemia (CLL). Additionally, preclinical data became publicly available today demonstrating the synergistic potential of the anti-CD38 antibody MOR202 and pomalidomide, a newly approved immunomodulatory agent in multiple myeloma therapy.

“We are delighted to publish this substantial package of clinical and preclinical data providing further validation for our lead cancer compounds MOR208 and MOR202. For MOR208, we are in particular looking forward to presenting first results for the Phase 2a study in NHL and the presentation of final results for the Phase 1/2a trial in CLL from our collaborators Ohio State University and Xencor at this year’s ASH meeting in December,” commented Dr. Arndt Schottelius, Chief Development Officer of MorphoSys AG.

List of All Abstracts:

A Phase IIa, Open-Label, Multicenter Study of Single-Agent MOR00208, an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma

Final Results and Follow-up of a Phase I Study of the Fc Engineered CD19 Antibody XmAb®5574 (aka MOR00208) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Synergistic in vitro Activity of MOR202, a Fully Human CD38 Antibody, in Combination with Pomalidomide

The full abstract can be accessed online at www.hematology.org/Meetings/Annual-Meeting and http://bloodjournal.hematologylibrary.org/.

A research paper presenting and discussing the results of the Phase I Study of MOR208 in CLL/SLL was recently published in the online issue of the peer-reviewed medical journal BLOOD: http://www.bloodjournal.org/content/early/2014/10/09/blood-2014-08-593269
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.

Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 90 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla® and Ylanthia® and 100 billion high potentials® are registered trademarks of MorphoSys AG.
Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR

Mario Brkulj
Associate Director Corporate Communications & IR

Alexandra Goller
Specialist Corporate Communications & IR

Jessica Rush
Specialist Corporate Communications & IR

Tel: +49 (0) 89 / 899 27-404
investors@morphosys.com